What is CELL ESSENTIALS?
CELL ESSENTIALS, established in 1998 and based in Boston, operates as a Contract Research Organization (CRO) with a specialized focus on antibody production and cell biology services. The company caters to critical areas such as diagnostics, drug discovery, and broader research initiatives. Their core competencies encompass custom hybridoma development, monoclonal antibody production, large-scale cell culture, and sophisticated cell-based assay development. CELL ESSENTIALS is dedicated to delivering scientific excellence and superior service, providing tailored solutions for both small and large-scale projects within the life sciences ecosystem.
How much funding has CELL ESSENTIALS raised?
CELL ESSENTIALS has raised a total of $61K across 1 funding round:
Debt
$61K
Debt (2021): $61K with participation from PPP
What's next for CELL ESSENTIALS?
The significant Series B/C stage funding context suggests CELL ESSENTIALS is poised for a period of accelerated growth and market penetration. This strategic backing will likely fuel advancements in their service offerings, potentially expanding their research capabilities and client base. The company's focus on custom solutions in antibody production and cell biology positions them to capitalize on the increasing demand for specialized CRO services in the pharmaceutical and biotechnology industries. Future developments may include scaling operations, enhancing technological infrastructure, and forging new strategic partnerships to further solidify their market presence.
See full CELL ESSENTIALS company page
